Dernières nouvelles pour Cardinal Health (NYSE:CAH) Stock

Cardinal Health

Cardinal Health is one of three leading pharmaceutical wholesalers in the us, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the us pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Cardinal Health Inc

CARRIER ALLIANCE HLDGS by Carrier Alliance Holdings, Inc.

Carrier Alliance Holdings Inc

CELESTIAL ASIA SECS NEW by Celestial Asia Secs Holdings Ltd.

Celestial Asia Securities Holdings Ltd

Caro Holdings Inc

EVOLUTION MINING LTD ORD by Evolution Mining Ltd.

Evolution Mining Ltd

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) is &#8220;up too much&#8230; You got to let it come down.&#8221;
On Nov. 22, JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60.
Cencora, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) can go lower and he prefers Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)<a href="https://www.benzinga.com/quote/COR"> to it</a>.
On Jan. 2, Cencora announced the completion of its previously announced acquisition of Retina Consultants of America, a leading management services organization of retina specialists.
Cramer said he would be &#8220;careful&#8221; with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
On Dec. 20, Novo Nordisk released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg, and placebo, all <a href="https://www.benzinga.com/government/regulations/24/12/42623343/exclusive-weight-loss-market-experts-scoop-up-novo-nordisk-stock-after-worst-drop-since-2002-following-drug-trial-miss">administered once-weekly.</a>
PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) right now, is in the &#8220;crosshairs of the GLP-1 situation,&#8221; Cramer said.
On Jan. 7, Piper Sandler analyst Mike Lavery initiated coverage on PepsiCo with an Overweight rating and announced a price target of $171.
Price Action:
<ul>
<li>Novo Nordisk shares fell 2% to settle at $83.34 on Tuesday.</li>
<li>PepsiCo shares fell 0.6% to close at $145.40 during the session.</li>
<li>Cencora shares gained 2.3% to settle at $234.24.</li>
<li>Lemonade shares fell 6.3% to settle at $36.14 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Image: Shutterstock

Long Ideas

News

Markets

Media

Trading Ideas

LMND

Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower

BofA Securities predicts that headline risks affecting the Healthcare Tech &amp; Distribution sector in 2024 will likely continue in 2025.
Key areas of concern include pharmacy benefit managers (PBMs), retail pharmacies, distributors, fertility benefits, and direct-to-consumer (D2C) pharmacies.
While regulatory pressure on PBMs is expected to persist, the analyst believes this will mainly impact profit margins and growth rates rather than lead to major changes in the business model.
Potential policy shifts under the next administration could involve adjustments to the Inflation Reduction Act, expanded access to health savings accounts (HSAs), and increased support for fertility benefits.
BofA upgraded Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from <a target="_blank" href="https://www.benzinga.com/quote/CAH/analyst-ratings" rel="noreferrer noopener">Neutral to Buy</a>. The analyst notes Cardinal Health&#8217;s core pharmaceutical segment is growing faster than its competitors, with this trend expected to strengthen in the coming year.
Also Raed: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41684029/cardinal-health-raises-2025-profit-outlook-again-helped-by-strong-drug-distribution-business" rel="noreferrer noopener">Cardinal Health Raises 2025 Profit Outlook Again, Helped By Strong Drug Distribution Business</a>
The company is benefiting from a unique advantage in its pharmacy benefit management (PBM) business, which could add 2-3 percentage points to earnings per share growth through fiscal 2026.
Despite its stronger growth potential, Cardinal&#8217;s stock is trading at a notable discount compared to McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), but this gap is likely to close or reverse within the next year.
BofA has also upgraded Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) from <a target="_blank" href="https://www.benzinga.com/quote/HSIC/analyst-ratings" rel="noreferrer noopener">Underperform to Buy</a> and raised the price target from $69 to $84, recognizing it as a top-tier dental business poised for long-term earnings growth.
The company is recovering from last year&#8217;s cybersecurity incident, which should <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752173/henry-schein-q3-earnings-sees-recovery-from-cyber-incident-says-dental-equipment-business-shows-sta" rel="noreferrer noopener">boost reported figures</a>.
With these challenges behind it and expectations now more realistic, the analyst writes Henry Schein offers a strong opportunity to benefit from a recovering dental market.
The company could see additional upside in the medium to long term, driven by a shift toward private-label products and a growing focus on specialty services. The analyst notes the price target of $84 is reasonable given its position at a market low.
Price Action: At the last check Tuesday, CAH stock was up 0.61% at $120.36, and HSIC stock was down 0.08% at $71.70.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42853126/phillips-66-powers-up-with-22-billion-deal-for-epic-y-grades-ngl-business" target="_blank" rel="noreferrer noopener">Phillips 66 Powers Up With $2.2 Billion Deal For EPIC Y-Grade&#8217;s NGL Business</a></li>
</ul>
Photo by Casimiro PT via Shutterstock

Analyst Color

Large Cap

Upgrades

Health Care

Analyst Ratings

General

HSIC

Headline Risks Affecting Healthcare Tech & Distribution Sector Will Likely Continue in 2025: BofA Analyst

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group analyst Elizabeth Anderson upgraded the rating for Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from In-Line to Outperform and maintained the price target of $140. Cardinal Health shares closed at $119.63 on Monday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan analyst Kenneth Worthington upgraded Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Underweight to Neutral and boosted the price target from $20 to $43. Robinhood shares closed at $42.71 on Monday. <a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc analyst Matthew Gillmor upgraded the rating for Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) from Sector Weight to Overweight and announced a $70 price target. Acadia Healthcare shares closed at $44.85 on Monday. <a href="https://www.benzinga.com/quote/ACHC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Aneesha Sherman upgraded the rating for Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from Market Perform to Outperform. Lululemon shares closed at $395.31 on Monday. <a href="https://www.benzinga.com/quote/LULU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Michael Turrin upgraded Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Equal-Weight to Overweight and raised the price target from $150 to $200. Snowflake shares closed at $163.08 on Monday. <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying HOOD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-1024x603.png" alt="" class="wp-image-721866" style="width:586px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-1024x603.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34.png 1155w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Pre-Market Outlook

ACHC

HOOD

LULU

SNOW

This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Evercore ISI Group analyst Elizabeth Anderson upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from In-Line to Outperform and maintains the price target from $140 to $140.

Price Target

Evercore ISI Group Upgrades Cardinal Health to Outperform, Maintains Price Target to $140

B of A Securities analyst Michael Cherny upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Neutral to Buy and raises the price target from $132 to $145.

B of A Securities Upgrades Cardinal Health to Buy, Raises Price Target to $145

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $127 to $136.

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $136

<a href="https://www.youtube.com/watch?v=fjFI9jPVh-A" title="https://www.youtube.com/watch?v=fjFI9jPVh-A">https://www.youtube.com/watch?v=fjFI9jPVh-A</a>

Biotech

Macro Economic Events

Global

Economics

President-Elect Donald J. Trump Says 'We're Going To Knock Out The Middlemen' Who Are Keeping Drug Prices High

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wolfe Research analyst Darrin Peller upgraded the rating for PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) from Peer Perform to Outperform and announced a $107 price target. PayPal shares closed at $89.40 on Thursday. See how other analysts view this stock.</li>
<li>B of A Securities analyst Tal Liani upgraded Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) from Neutral to Buy and raised the price target from $70 to $95. Ciena shares closed at $84.52 on Thursday. <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Kyle Peterson upgraded Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Hold to Buy and announced a $100 price target. Upstart shares closed at $77.08 on Thursday. See how other analysts view this stock.</li>
<li>UBS analyst A.J. Rice upgraded the rating for Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Neutral to Buy and increased the price target from $79 to $80. Centene shares closed at $58.00 on Thursday. <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Stephen Baxter upgraded the rating for Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Underweight to Equal-Weight and raised the price target from $101 to $127. Cardinal Health shares closed at $117.46 on Thursday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PYPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="622" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-1024x622.png" alt="" class="wp-image-691544" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-1024x622.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-768x466.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>

CIEN

PYPL

UPST

This PayPal Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wells Fargo analyst Stephen Baxter upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Underweight to Equal-Weight and raises the price target from $101 to $127.

Wells Fargo Upgrades Cardinal Health to Equal-Weight, Raises Price Target to $127

TTOO

T2 Biosystems To License Proprietary Technology For Direct-From-Whole-Blood Sepsis Pathogen Detection, Aiming To Generate Non-Dilutive Capital, Create Royalty Revenue Streams, And Broaden Adoption Of FDA-Cleared Diagnostics Powered By T2MR Detection And Adaptable Sample Processing Technology

FDA Says Cardinal Health Removes Some Monoject U-100 mL Insulin Syringe Luer Lock With Tip Cap Soft Packs

Cardinal Health Announced The U.S. Launch Of Its Kendall SCD SmartFlow Compression System, The Next Generation Of The Kendall Compression Series Offering An Enhanced Clinician And Patient Experience

Cardinal Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) short percent of float has fallen 26.42% since its last report. The company recently reported that it has 5.50 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.61 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cardinal Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732035620_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cardinal Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cardinal Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cardinal Health's peer group average for short interest as a percentage of float is 5.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Cardinal Health's Recent Short Interest

<ul>
<li>Acquisition of a majority stake in GI Alliance, the country's leading&nbsp;gastroenterology management services organization, to accelerate Cardinal Health's multi-specialty growth strategy</li>
<li>Acquisition of the Advanced Diabetes Supply Group, a leading national direct-to-patient provider of diabetes medical supplies, to accelerate Cardinal Health's at-Home Solutions growth strategy</li>
<li>Company announces plan to hold Investor Day in June 2025</li>
</ul>
Cardinal Health will acquire a majority stake in GI Alliance (GIA), the country's leading gastroenterology (GI) management services organization (MSO), from a combination of GIA physician owners and funds managed by affiliates of Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>). Cardinal Health will purchase its majority stake for approximately $2.8 billion in cash, which will represent 71% ownership. GIA will operate as a platform within Cardinal Health's Pharmaceutical and Specialty Solutions segment. &nbsp;
Cardinal Health will also acquire the Advanced Diabetes Supply Group (ADSG), one of the country's leading diabetic medical supplies providers, for approximately $1.1 billion in cash. ADSG will merge with Cardinal Health's at-Home Solutions business.

Reported Earlier, Cardinal Health Accelerates Strategic Growth With $3.9B GI Alliance Acquisition And $1.1B Advanced Diabetes Supply Group Buyout

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $119 to $127.

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $127

Deutsche Bank analyst George Hill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Hold and raises the price target from $119 to $124.

Deutsche Bank Maintains Hold on Cardinal Health, Raises Price Target to $124

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $134 to $139.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $139

Mizuho analyst Ann Hynes maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Neutral and raises the price target from $110 to $120.

Mizuho Maintains Neutral on Cardinal Health, Raises Price Target to $120

Barclays analyst Stephanie Davis maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $117 to $133.

Barclays Maintains Overweight on Cardinal Health, Raises Price Target to $133

Wall Street rebounded Friday following Thursday&#8217;s selloff, yet midday gains were still insufficient to prevent a second consecutive weekly decline for the S&amp;P 500, currently <a href="https://www.benzinga.com/markets">down 1% for the week. </a>
Concerns over tech earnings eased after Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) outperformed expectations, restoring some risk appetite and supporting the sector rebound.
Amazon shares surged over 6%, heading for their best session since February.
The Nasdaq 100, up by 1.1%, outperformed the S&amp;P 500, up 0.8%. 
In economic data, the U.S. economy added just 12,000 jobs in October, a steep drop from the 223,000 gain in September and well below the forecast of 113,000, as hurricanes and strikes led to hiring freezes nationwide. 
Despite the weak job figures, the unemployment rate held steady at 4.1%, indicating companies chose to retain workers rather than downsize.
The ISM Manufacturing PMI signaled contraction for the seventh consecutive month in October, with the index missing estimates.
Oil prices experienced a volatile session, initially spiking on reports of an imminent retaliatory attack by Iran on Israel before pulling back as those concerns faded. Gold edged down 0.1%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dipped 0.3%, slipping below the $70,000 mark.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,123.15</td>
<td>1.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,161.88</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,751.05</td>
<td>0.8%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,209.70</td>
<td>0.6%</td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.9% to $573.75.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 1.1% to $422.09.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.2% to $489.80.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.8% to $219.26.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 2%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.4%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), down 1.6%.</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), up over 6%.</li>
<li>Atlassian Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), up 20%.</li>
<li>Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), down 0.7%.</li>
<li>Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), up 2.8%.</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), up 13%.</li>
<li>Dominon Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>), down 0.2%.</li>
<li>Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), up 6%.</li>
<li>CBOE Global Markets Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#NYSE">CBOE</a>), down 2.9%.</li>
<li>Waters Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), up 17%.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41690576/apple-q4-results-better-than-feared-analysts-highlight-iphone-16-demand-apple-intel">Apple Q4 Results &#8216;Better-Than-Feared&#8217;: Analysts Highlight iPhone 16 Demand, Apple Intelligence Opportunity After &#8216;Rock Solid Quarter&#8217;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings

Equities

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Tech

ETFs

$BTC

AAPL

AMZN

CBOE

CHTR

SPDR Dow Jones Industrial Average ETF Trust

INTC

TEAM

Select Sector SPDR-Consumer Discretionary

Tech Stocks Surge But S&P 500 Faces Second Weekly Decline, Amazon Rallies, Bitcoin Drops Below $70,000: What's Driving Markets Friday?

Dividend Champion, Contender, And Challenger Highlights: Week Of December 29

KNG: Uncompelling Buy-Write ETF

BDJ: 9% Income, 8% Discount, And Lower Volatility

BofA analyst Michael Cherny upgraded Cardinal Health (CAH) to Buy from Neutral with a price target of $145, up from $132. Cardinal's organic growth...

Cardinal Health upgraded to Buy from Neutral at BofA

BofA lowered the firm's price target on McKesson (MCK) to $650 from $680 and keeps a Buy rating on the shares. Specialty will remain a key growth a...

McKesson price target lowered to $650 from $680 at BofA

Cardinal Health upgraded to buy by BofA

Cardinal Health (CAH – Research Report) received a Buy rating and price target from Evercore ISI analyst Elizabeth Anderson CFA today. The company'...

Positive Report for Cardinal Health (CAH) from Evercore ISI

Evercore ISI upgraded Cardinal Health (CAH) to Outperform from In Line with an unchanged price target of $140. The firm sees the company's fiscal 2...

Cardinal Health upgraded to Outperform from In Line at Evercore ISI

Cardinal Health upgraded by Evercore ISI to outperform

Cardinal Health (CAH – Research Report) received a Buy rating and a $144.00 price target from TD Cowen analyst Charles Rhyee today. The company's s...

TD Cowen upgrades Cardinal Health (CAH) to a Buy

ALLE

ARES

AVGO

BANF

BKUTK

BPOP

CADE

CFFI

CHDN

CHRW

CINF

COFS

CSCO

CSGS

CSWC

CTBI

CTRE

CUBE

EFSC

ENSG

EPRT

FCPT

FFIN

FFMR

FISI

FITB

FMCB

FNLC

FSFG

FTHI

FULT

GATX

HWBK

IIPR

INDB

INGR

ISTR

JEPI

LANC

LAND

LDOS

LECO

MBIN

MDLZ

MORN

MPWR

MSFT

NDSN

NXRT

OLED

PINE

POWI

QDPL

REXR

RGLD

SCHD

SFBS

SFNC

SPXX

SSNC

STAG

STLD

SWBI

SYBT

TFII

THFF

TOWN

TROW

UBSI

UMBF

UNTY

UTMD

VRSK

WSBC

XYLD

XYLG

YORW

Press Releases

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

Cardinal Health celebrates medical product distribution center grand opening in Massachusetts

Cardinal Health Reports First Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

Dividends

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health announces two strategic additions to its portfolio

GI Alliance to Partner with Cardinal Health Creating a Scaled Multi-Specialty Managed-Services Platform to Benefit Physicians and Patients

Court Square Capital Partners Announces Sale of Advanced Diabetes Supply Group

Cardinal Health launches Kendall SCD SmartFlow™ Compression System

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2025 on January 30

AdaptHealth

Akso Health Group - American Depositary Shares

Akso Health

Comments

Cardinal Health

Actualités

Dernières nouvelles pour Cardinal Health (NYSE:CAH) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL